GlassScriptPhysician profile
Marvin I Ruderman
NPI 1427129006
$18,523.16
in general payments reported to CMS, 2019-2025
53 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,145 · 2020: $4,673 · 2021: $5,867 · 2022: $2,038 · 2023: $1,292 · 2024: $1,339 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,689.42 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,363.14 | 2019-2022 | |
| Abbvie INC. | $3,083.44 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $1,107.00 | 2019-2024 | Austedo Xr, Austedo |
| Biogen, INC. | $778.09 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Neurocrine Biosciences, INC. | $682.72 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $678.76 | 2019-2025 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $619.03 | 2020-2021 | |
| Csl Behring | $604.51 | 2019-2025 | Hizentra |
| Lilly USA, LLC | $587.07 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Genentech USA, INC. | $538.20 | 2019-2025 | Ocrevus Zunovo |
| Argenx US, INC. | $492.33 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $468.68 | 2019-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $363.13 | 2020-2024 | Zeposia |
| Jazz Pharmaceuticals INC. | $319.22 | 2019-2020 | |
| Horizon Therapeutics Plc | $265.00 | 2021-2023 | Uplizna |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Ruderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.